BRCA2 and cancer: While most heterozygous carriers do not appear to have significantly increased cancer risks [62,63], susceptibility to cancer, including CRC, is well established for carriers of heterozygous pathogenic variants in FANCS/BRCA1, FANCD1/BRCA2, FANCN/PALB2, FANCJ/BRIP1, and FANCO/RAD51C [62,64].